<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249183</url>
  </required_header>
  <id_info>
    <org_study_id>RPV03C</org_study_id>
    <nct_id>NCT01249183</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old</brief_title>
  <official_title>An Open-label, Randomised, Multicentre Study to Evaluate the Immunogenicity and Safety of a Booster Dose of Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Adsorbed Vaccine (REPEVAX) Administered Concomitantly Versus Non-concomitantly With an Influenza Vaccine (VAXIGRIP) to Subjects of 60 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives:

      To demonstrate that REPEVAX and VAXIGRIP administered concomitantly in subjects 60 years of
      age and older are at least as immunogenic as REPEVAX or VAXIGRIP administered separately.

      Secondary objectives:

      •Secondary immunogenicity objectives: To describe the immune responses 28 days after
      concomitant or separate administration of REPEVAX and VAXIGRIP in subjects 60 years of age
      and older To describe the immune response of VAXIGRIP according to European Medicines Agency
      criteria in subjects 60 years of age and older (Note for Guidance, 1997: 28)

      •Secondary safety objective: To describe the safety profile after vaccination in each group
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diphtheria seroprotection rate</measure>
    <time_frame>28 to 35 days after vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tetanus seroprotection rate</measure>
    <time_frame>28 to 35 days after vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Polio seroprotection rate</measure>
    <time_frame>28 to 35 days after vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pertussis antibody titre</measure>
    <time_frame>28 to 35 days after vaccine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Flu geometric mean of titres ratio</measure>
    <time_frame>28 to 35 days after vaccine administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited injection-site reactions, solicited systemic adverse reactions</measure>
    <time_frame>From Day 0 to Day 7 following REPEVAX vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site adverse reactions and systemic adverse events</measure>
    <time_frame>From Day 0 to Day 28 following REPEVAX and/or VAXIGRIP vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of Serious adverse events</measure>
    <time_frame>From the first visit to the last visit of the subject</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">954</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>1- VAXIGRIP and REPEVAX concomitantly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2-REPEVAX 28 days after VAXIGRIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Concomitant administration</intervention_name>
    <description>1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)</description>
    <arm_group_label>1- VAXIGRIP and REPEVAX concomitantly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Separate administration</intervention_name>
    <description>1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later</description>
    <arm_group_label>2-REPEVAX 28 days after VAXIGRIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥60 years

          -  At least one documented booster dose with a tetanus- and diphtheria-containing vaccine
             between 5 and 15 years

          -  No influenza vaccine administered during the last 6 months

        Exclusion Criteria:

          -  Receipt of a booster dose with a tetanus or diphtheria- or poliomyelitis- containing
             vaccine within the last 5 years

          -  Receipt of pertussis-containing vaccine or pertussis disease within the last 10 years

          -  Receipt of medication / vaccine that may interfere with study assessments

          -  Febrile illness or moderate or severe acute illness/infection

          -  History of hypersensitivity or anaphylactic or other allergic reactions to any of the
             vaccine components, or history of a life-threatening reaction to the study vaccines or
             a vaccine containing any of the same substances

          -  History of Guillain Barré syndrome or brachial neuritis following a previous
             vaccination

          -  History of encephalopathy of unknown origin within 7 days after immunization with a
             pertussis-containing vaccine or unstable neurological disorders

          -  Known or suspected immune dysfunction

          -  Thrombocytopenia, bleeding disorder or anticoagulants contraindicating intramuscular
             vaccination

          -  Chronic disease that is unstable or any intercurrent illness that might interfere with
             the ability to participate fully in the study; or interfere with evaluation of the
             vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Châtellerault</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Gieres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Hérouville Saint-Clair</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Tierce</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Heilbronn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site</name>
      <address>
        <city>Reichenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2010</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis (acellular, component)</keyword>
  <keyword>Diphteria</keyword>
  <keyword>Biological / vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

